Cybin Inc (CYBN) Stock Price, Quote & News

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology

Sector: Healthcare

Website: cybin.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

BobJohnBuoy666 Dec. 28 at 10:25 PM

$CYBN 1 year chart; almost a perfect bullish doji…on volume…consolidating for its 5th year inside bull parent candle. Many will sell in the 30s…

0 · Reply

BioTechHealthX Dec. 27 at 11:08 PM

$CYBN Cybin Inc (NASDAQ: CYBN) is emerging as one of the most talked-about mental health stocks as it advances late-stage psychedelic drug development for major depressive disorder and anxiety, signaling a potential shift in how mental healthcare is treated. https://biotechhealthx.com/biotech-news/cybin-cybn-is-quietly-rewriting-the-future-of-mental-healthcare-heres-why-investors-are-paying-attention/

0 · Reply

Mastercharts Dec. 27 at 9:22 PM

Stocks at record highs. Silver pulling in amateurs — buying climax or just getting started? Gold breaks out. Dollar weakens. Copper says stocks are still OK. Charts + data, not opinions 👇 https://www.masterchartstrading.com/blog/dec-27-2025-stocks-at-new-highs-as-silver-runs-hot-breadth-says-rally-isnt-done-psychedelics $SPY $SLV $GLD $CYBN

2 · Reply

Mastacash Dec. 27 at 5:00 PM

$CYBN. Check out my post on X. Elon musk had direct contact with then ceo of cybn Doug. The eve is coming. Time to be on board or you’ll miss the train. https://x.com/mastacash_/status/2004957727731184053?s=12&t=jCHCXrWm93J_2H0pU9P1Fw

0 · Reply

BelieveinthePK Dec. 27 at 2:50 AM

$CYBN Nothing more to add here except speculation. This one will run to 300 over the next 24 months.

1 · Reply

starbucks_cups_with_rum Dec. 27 at 12:00 AM

$CYBN $CYBN congrats to all, had paper hands here because I thought it was a daily microdose but turned out to be monthly

1 · Reply

BobJohnBuoy666 Dec. 26 at 8:52 PM

$CYBN go to 1hr chart and look how methodical this uptrend has been. Patient, incremental tests of overhead supply. Chances they gap launch this into NASDAQ up listing feel high

1 · Reply

Mastacash Dec. 26 at 8:13 PM

$CYBN providing analysis and thoughts on our speculative holdings. Free Newsletter starting 2026. Give me a follow and you can see all posts and content free. Just like I flagged below, more winners to come in 2026.

1 · Reply

Alex1710 Dec. 26 at 6:50 PM

$CYBN When you compare Atai Beckley to Cybin there is 1$B market cap difference. Atai targets the same psychological disorders and is not more advance in clinical trials than Cybin is, except Atai has one more compound in mid P2.

0 · Reply

ZRadly Dec. 26 at 4:41 PM

$CYBN This ticker keeps on giving. Good roller-coaster. Will continue this bankroll ticker to my space tickers.. See you on mars...😉 sidu fjet rklb

0 · Reply

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Nov 13, 2025, 3:11 PM EST - 6 weeks ago

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 7:20 AM EST - 6 weeks ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:30 AM EST - 6 weeks ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:30 AM EST - 7 weeks ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 7:30 AM EST - 7 weeks ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 7 weeks ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 2 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 2 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 3 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 11, 2025, 3:59 PM EDT - 3 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 7:30 AM EDT - 3 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 4, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 4 months ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 4 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 13, 2025, 5:30 PM EDT - 4 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 7, 2025, 7:30 AM EDT - 5 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 17, 2025, 7:30 AM EDT - 5 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 6 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 10:03 PM EDT - 6 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 9:27 PM EDT - 6 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 13, 2025, 7:45 AM EDT - 7 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 12, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 11, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 3, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

May 22, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 20, 2025, 7:30 AM EDT - 7 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 15, 2025, 7:30 AM EDT - 8 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 14, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 8, 2025, 7:30 AM EDT - 8 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 1, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Apr 23, 2025, 7:30 AM EDT - 8 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 21, 2025, 8:00 AM EDT - 8 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Feb 10, 2025, 9:48 PM EST - 11 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Jan 15, 2025, 12:07 PM EST - 1 year ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 13, 2025, 7:30 AM EST - 1 year ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 9, 2025, 5:00 PM EST - 1 year ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 10, 2024, 7:30 AM EST - 1 year ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 4, 2024, 7:30 AM EST - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Nov 18, 2024, 7:00 AM EST - 1 year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 14, 2024, 7:30 AM EST - 1 year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

BobJohnBuoy666 Dec. 28 at 10:25 PM

$CYBN 1 year chart; almost a perfect bullish doji…on volume…consolidating for its 5th year inside bull parent candle. Many will sell in the 30s…

0 · Reply

BioTechHealthX Dec. 27 at 11:08 PM

0 · Reply

Mastercharts Dec. 27 at 9:22 PM

2 · Reply

Mastacash Dec. 27 at 5:00 PM

0 · Reply

BelieveinthePK Dec. 27 at 2:50 AM

$CYBN Nothing more to add here except speculation. This one will run to 300 over the next 24 months.

1 · Reply

starbucks_cups_with_rum Dec. 27 at 12:00 AM

$CYBN $CYBN congrats to all, had paper hands here because I thought it was a daily microdose but turned out to be monthly

1 · Reply

BobJohnBuoy666 Dec. 26 at 8:52 PM

$CYBN go to 1hr chart and look how methodical this uptrend has been. Patient, incremental tests of overhead supply. Chances they gap launch this into NASDAQ up listing feel high

1 · Reply

Mastacash Dec. 26 at 8:13 PM

1 · Reply

Alex1710 Dec. 26 at 6:50 PM

0 · Reply

ZRadly Dec. 26 at 4:41 PM

$CYBN This ticker keeps on giving. Good roller-coaster. Will continue this bankroll ticker to my space tickers.. See you on mars...😉 sidu fjet rklb

0 · Reply

Mastacash Dec. 26 at 4:12 PM

$CYBN RSI of 80, we haven’t seen this strength since 2023, and this move is not a spike to dump, it’s been methodical. The volume is real, the price action is real, the sentiment shift is real..

0 · Reply

thepalace2007 Dec. 26 at 2:43 PM

$CYBN easy double your money

0 · Reply

Mastacash Dec. 26 at 1:50 PM

$CYBN my top speculative pick for 2026.

0 · Reply

1iquid Dec. 25 at 2:11 PM

💎 Liquid® Live Actionable Trade Asset: $CYBN Contracts: $CYBN August 21, 2026 $12 Calls Scale in: $1.36- $1.66 Scale out: $5.29-$9.07 Profit Potential : 327% ROI Blended Join 💎 Here: https://1iquid.com

0 · Reply

blago04 Dec. 24 at 5:05 PM

$CYBN who here is also interested in CMPS? Thinking of starting to build a position there first with this as a secondary for some added "torque"

1 · Reply

microdoseme Dec. 24 at 5:00 PM

$CYBN Must have some ambitous data forthcoming. Happy Holidays to all.

0 · Reply

biochirp Dec. 24 at 3:59 PM

$CYBN holding for data readout, nice move tho

0 · Reply

TrendDecoded Dec. 24 at 4:58 AM

$GOOG $CMPS $CYBN Google is the only company that owns the entire AI stack. 1. Chips: TPUs 2. Infrastructure: Google Cloud 3. Foundation Models: Deepmind 4. Applications: Gemini Every layer matters. The more layers you own, the bigger your advantage. In-depth analysis and sharing of practical investment strategies, interpreting real-time market trends @TrendDecoded

1 · Reply

brunoq14 Dec. 24 at 4:49 AM

$CMPS $CYBN moves to Nasdaq January 5, under new symbol HELP.

0 · Reply

brunoq14 Dec. 24 at 4:44 AM

$CYBN Moves to Nasdaq January 5, trading under new symbol: HELP.

0 · Reply

RkyMtnChi Dec. 24 at 12:50 AM

$CYBN I've admittedly flipped this stock more times than I can count over the last few years, knowing that approval was still a ways down the road. But long-term, it's still the ace in my hand and I'm done with flipping shares, as their trials continue to produce great results and the light at the end of the tunnel draws nearer. My only regret is that I didn't buy more shares when it dipped back into the 5s. If it dips again, I'll fix that mistake.

2 · Reply

Mastacash Dec. 24 at 12:28 AM

$JMIA $CYBN I was calling a bottom in this name last year as the stock was at $2, this board was dead and so was the stock. Now it’s at $13 and will run to the $20S next year if growth continues. For anyone interested my new buy next year is $CYBN, a small cap psychedelic stock that’s is deeply undervalued but the science and results so far have been impressive, as well as the shift in regulations for alternative medicine (maryj going to sched 3) if you ever heard RFK jr speak, Psilocybin is next. Cheers.

0 · Reply

Market Cap	210.07M
Revenue (ttm)	0.00
Net Income (ttm)	-81.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,025,200
Avg Vol	892,218
Day's Range	N/A - N/A
Shares Out	25.19M
Stochastic %K	97%
Beta	0.67
Analysts	Strong Sell
Price Target	$45.00